Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04952753
Title Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)
Recruitment Recruiting
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals

colorectal adenocarcinoma


Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793

Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | CAN

Additional content available in CKB BOOST